Robert Perkins

Robert Perkins is a Board-certified Internist and Nephrologist serving as the Vice President of Renal and Cardiovascular Medical Affairs at Bayer since January 2023, where responsibilities include leading a team of 60 and managing a substantial budget to support innovative therapies for diabetic kidney disease and heart failure. Prior roles include Executive Medical Director at Novartis, from January 2020 to January 2023, where strategic pre-launch medical functions for Iptacopan were orchestrated, and Medical Head at AstraZeneca, from January 2019 to January 2020, managing a team for the launch of Roxadustat for anemia of CKD. Robert Perkins holds an AB in English Literature and Language from Harvard University and is currently pursuing a Master of Public Health in Epidemiology at Johns Hopkins University Bloomberg School of Public Health.